🕵️ Nuvectis Pharma, Inc. ($NVCT)

SEC insider & ownership activity, last 12 months · CIK 1875558 · every row links its SEC filing

Over the last 12 months insiders bought $2.3M with no open-market selling against it. Mosseri Marlio Charles bought $1.9M (Oct–Jun). No red-flag 8-Ks in the window.

Aug 2025: net +$0 Sep 2025: net +$0 Oct 2025: net +$957K Nov 2025: net +$168K Dec 2025: net +$0 Jan 2026: net +$0 Mar 2026: net +$0 Mar 2026: net +$0 Apr 2026: net +$0 May 2026: net +$0 Jun 2026: net +$1.2M Jul 2026: net +$0
Monthly net open-market insider flow, last 12 months (up = net buying)

Insider flow

4 buyers, $2.3M (8 lots) · 0 sellers, $0 (0 lots)

InsiderBuysBoughtSellsSoldLast
Mosseri Marlio Charles4$1.9M 0Jun 30, 2026
Bentsur Ron2$279K 0Jun 30, 2026
Sanchez Juan1$75K 0Nov 5, 2025
Matthew L. Kaplan1$64K 0Nov 5, 2025

5%+ holders

No current 5%+ beneficial-ownership positions on file.

Planned insider sales (Form 144)

No sale notices filed in the last 12 months.

Material events (8-K)

ItemEvent date
Material agreement (1.01)Jun 29, 2026 filing ↗
Other events (8.01)Jun 29, 2026 filing ↗
Financial Statements and Exhibits (9.01)Jun 29, 2026 filing ↗
Other events (8.01)Jun 29, 2026 filing ↗
Material agreement (1.01)Jun 22, 2026 filing ↗
Other events (8.01)Jun 22, 2026 filing ↗
Financial Statements and Exhibits (9.01)Jun 22, 2026 filing ↗
Shareholder vote (5.07)Jun 11, 2026 filing ↗
Earnings (2.02)May 5, 2026 filing ↗
Financial Statements and Exhibits (9.01)May 5, 2026 filing ↗
Earnings (2.02)Feb 11, 2026 filing ↗
Financial Statements and Exhibits (9.01)Feb 11, 2026 filing ↗
Earnings (2.02)Nov 4, 2025 filing ↗
Financial Statements and Exhibits (9.01)Nov 4, 2025 filing ↗
Officer/director changes (5.02)Sep 22, 2025 filing ↗
Financial Statements and Exhibits (9.01)Sep 22, 2025 filing ↗
Earnings (2.02)Aug 5, 2025 filing ↗
Financial Statements and Exhibits (9.01)Aug 5, 2025 filing ↗